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Case Report
Against the Odds: Idiopathic Sudden Sensorineural





A 79-yr-old male was evaluated by the authors 4–6wk following a rapid decline in perceived hearing in the
right ear. Initial treatment with self-administered external ear canal irrigations and topical antibiotic pre-
scribed by the patient’s primary care physician resulted in no apparent improvement. The initial hearing
evaluation revealed a mild-to-severe sloping sensorineural loss above 1000 Hz in the left ear and a mod-
erately severe to severe sensorineural loss with a “flat” configuration in the right ear. There was normal
word recognition in the left ear, with no measurable word recognition in the right ear. Initial treatment with
oral steroids suggested some subjective improvement, and an intratympanic dexamethasone injection
was performed. A repeat audiogram obtained approximately 1 mo postinjection showed significant
improvement in pure tone thresholds and significant improvement in the word recognition score in
the right ear. One week later a second intratympanic injection was completed, again, with follow-up
in 1 mo. This case report reviews treatment options for idiopathic sudden sensorineural hearing loss
(ISSNHL), including usual time lines for treatment and expected outcomes and the specific treatments
and evaluation results for this patient for whom delayed treatment was unusually effective.
Key Words: Dexamethasone, idiopathic sudden sensorineural hearing loss, intratympanic injection,
steroid, sudden sensorineural hearing loss
Abbreviations: ISSNHL 5 idiopathic sudden sensorineural hearing loss; IT 5 intratympanic; MRI 5
magnetic resonance imaging; NIDCD 5 National Institute on Deafness and Communication Disorders;
SRT 5 speech recognition threshold; SSNHL 5 sudden sensorineural hearing loss; WRS 5 word
recognition score
T
he definition and treatment of sudden sensori-
neural hearing loss (SSNHL) is a topic of much
discussion and of some controversy in audiology
and otolaryngology. SSNHL is defined by the National
Institute on Deafness and Communication Disorders
(NIDCD) as a decline of at least 30 dB HL in three con-
tiguous frequencies over a period of up to 3 days.
NIDCD also reports that 90% of all SSNHL occurs uni-
laterally (NIDCD, 2003). The SSNHL could be a new
hearing loss or it could represent an incremental deteri-
oration in an ear with pre-existing hearing loss. In clin-
ical practice, the degree of certainty about the hearing
level at presentation compared to the “premorbid” hear-
ing ranges from being very certain, when the patient
has a full and documented audiological assessment, to
uncertain, due to having only patient report of some
pre-existing hearing loss, but with no documentation.
SSNHL is characterized by a sudden decline in hearing
of cochlear or retrocochlear origin. The cause of SSNHL
ismost often unknown; however, it can occur due to ves-
tibular schwannoma (Sauvaget et al, 2005), acoustic
trauma, Me´nie`re’s disease, cochlear hydrops, peril-
ymph fistula, mumps, head injury, multiple sclerosis,
meningitis, and other disorders (Mattox and Simmons,
1977). Sudden unilateral sensorineural hearing loss due
to anterior inferior cerebellar artery infarction has been
also been documented and described (Martines et al,
2011). Evaluation and assessment includes history,
physical audiological examination, appropriate labora-
tory tests, andmagnetic resonance imaging (MRI). Absent
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an identified cause, the SSNHL is referred to as idiopathic
sudden sensorineural hearing loss (ISSNHL).
Various theories have been postulated to explain
ISSNHL, and due to the abrupt onset, vascular inter-
ruption (Perlman et al, 1959; Belal, 1979) and viral
infection (Cole and Jahrsdoerfer, 1988; Vasama and
Linthicum, 2000) have been suggested. Additional theo-
ries of explanation of ISSNHL include ischemia of the
cochlea (Lin et al, 2008), autoimmune disease, and rup-
ture of Reissner’s membrane (Yoon et al, 1990). Of these
potential etiologies, those having a vascular basis and
those with viral basis have gained popularity.
The incidence of ISSNHLhas been estimated to be from
5 to 20 per 100,000 per year (Byl, 1984). More recently,
a retrospective cross-sectional study from Taiwan (Wu
et al, 2006) estimated the incidence at approximately
eight per 100,000per year.Considering that somenumber
of ISSNHL are not reported due to spontaneous recovery
over a short period of time or are simply not reported, the
true incidence is likely underestimated in the literature.
The rate of spontaneous recovery has been reported to be
as high as 65% (Mattox and Simmons, 1977; Vasama and
Linthicum, 2000). Themajority of spontaneous recoveries
occur within 2 wk, with many occurring in the first few
days (Mattox andSimmons, 1977). The occurrence at such
a relatively high rate of spontaneous recovery and the rel-
atively low incidence of occurrence of ISSNHL presents
challenges to researchers and clinicians investigating eti-
ologies and the efficacies of treatments. Importantly, sev-
eral factors have been reported to have a poor prognosis
for hearing recovery, including delay of treatment (Mattox
and Simmons, 1977; Byl, 1984; Haynes et al, 2007), age
younger than 15 and older than 59 (Byl, 1984), severe
vertigo, and severe-profound hearing loss (Mattox and
Simmons, 1977; Byl, 1984).
Medical management of patients with ISSNHL is not
straightforward, with dilemmas due to spontaneous re-
covery, heterogeneous pathophysiology of the ISSNHL,
and undertreatment and/or delayed treatment. In addi-
tion, treatmentmodalities have variedwidely in published
studies, further complicating the critical appraisal of treat-
ment efficacy. Several treatments have been used, includ-
ing antiviral and hemodilution mineral agents, vitamin
and herbal preparations, systemic steroids, niacin, hista-
mine, and hyperbaric oxygen (Conlin and Parnes, 2007).
More recently, intratympanic (IT) steroid injections have
been used (Hu and Parnes, 2009). The most generally
accepted treatment in North America is systemic steroids
(Chandrasekhar, 2003; Haynes et al, 2007). The efficacy of
systemic steroid therapy was established in several trials
(Wilson, 1980; Moskowitz et al, 1984). However, other
studies have questioned this finding (Cinamon, 2001;
Conlin and Parnes, 2007), and a recent Cochrane review
concluded that the effectiveness of steroids for treatment
of ISSNHL is unclear based upon a critical appraisal of
the currently available studies (Wei et al, 2006).
Due to the known risks associated with short- or long-
term systemic steroid therapy, such as immune suppres-
sion, weight gain, osteoporosis, avascular necrosis of the
hip, mood swings, and skin and endocrine changes, IT
steroids are becoming increasingly used in the United
States. Similar to other treatments, there is great vari-
ability between treatment regimens; however, use of
IT steroids has evolved into three primary approaches
for treatment of ISSNHL: initial or primary treatment
for ISSNHL without systemic steroids; adjunctive
treatment given concomitantly with systemic steroids
for ISSNHL; and as “salvage therapy” after failure of
systemic steroids for ISSNHL (Haynes et al, 2007). IT
steroid injection offers many advantages relative to sys-
temic steroid therapy, including ease of application,
that it is well-tolerated, and avoidance of potential risks
and side effects seen with systemic steroid therapy. The
risks of IT injection are uncommon (tympanic mem-
brane perforation, further hearing loss, acute otitis
media) and/or transient (vertigo, pain) (Haynes et al,
2007; Seggas et al, 2011).
Haynes et al (2007) retrospectively reviewed 40 patients
who underwent IT steroid injection for ISSNHL after fail-
ing to improve with initial systemic steroid therapy. Using
20 dB pure tone average (PTA) (three-frequency) or 20%
word discrimination improvement as a successful result,
39% demonstrated improvement if treated within 6 wk
of the start of the ISSNHL. No patient receiving dexame-
thasone injections after 36 days recovered hearing, using
the 20 dB/20% criteria.
Tsai et al (2011) performed a retrospective study of 128
subjects who received IT steroid treatment. Patients who
received IT therapy within 7 days of disease onset had a
significantly higher response (76%) when compared to
patients who received more delayed treatment (58%).
The authors also found greater improvement in the low
and midfrequencies (250, 500, and 1000 Hz) than at
higher frequencies (2000 and 4000 Hz).
A recent prospective clinical trial (Fu et al, 2011) eval-
uated 66 subjects with sudden profound unilateral sen-
sorineural loss of less than 2weeks duration. All subjects
received a 9 day course of intravenous steroids, a 7 day
course of Prostaglandin E1 intravenous infusion, and 30
days of hyperbaric oxygen therapy. Following this ther-
apy regimen, subjects were offered additional IT ther-
apy. Twenty-two subjects elected IT steroid therapy,
and 44 declined (control group). Audiograms obtained
prior to treatment and 30 days post-treatment revealed
a 30 dB or greater recovery rate of 77.27% for the IT
group and 81.81% for the control group (nonsignificant);
however, examination of data reported by the authors
suggests 5–10 dB greater improvement in the IT group
than the control group in the primary speech frequencies
(500, 1000, and 2000 Hz).
A thorough review of literature regarding IT steroid
treatment was undertaken by Hu and Parnes (2009).
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However, due to the heterogeneous nature of the stud-
ies, a meta-analysis was unable to be performed, and no
conclusions could be made regarding the effectiveness
of IT steroid injection therapy for ISSNHL. Recommen-
dations were made for more rigorously designed stud-
ies. Another recent literature review remarked upon
the same concerns of the quality and variability of avail-
able research (Seggas et al, 2011). This researcher, how-
ever, drew guarded conclusions, based on general results
rather than rigorous methodological analysis, favoring
the use of IT steroids in refractory ISSNHL and as an
initial therapy, as well as in patients unable to use sys-
temic steroids (Seggas et al, 2011).
CASE PRESENTATION
A79-yr-old male presented to the Department ofOtolaryngology–Head and Neck Surgery at
Washington University in St. Louis School of Medicine
with report of rapid unilateral hearing decline in his
right ear approximately four to six weeks prior to pre-
sentation at this clinic, which he attributed to excess
cerumen. Due to this assumption, he self-irrigated with
warm water. When the hearing loss remained, the pa-
tient was evaluated by his primary care physician and
placed on Ciprofloxacin Otic drops. There was no notice-
able improvement in hearing. He did not experience
pain, bleeding, or vertigo associated with the hearing
loss, canal irrigations, or topical antibiotic treatment.
He had intermittent bilateral tinnitus for many years;
however, the tinnitus in the right ear became more pro-
nounced with the onset of the hearing loss. The patient
reported a history of significant noise exposure while
growing up on a farm and lifelong exposure to noise
with large machinery and equipment.
In the month prior to the decline in hearing, he
developed pneumonia with chest pain and shortness
of breath. He was treated with oral antibiotics, and
his symptoms resolved completely prior to his appoint-
ment in our office. His past medical history includes
hypertension, acid reflux, hypothyroidism, and coro-
nary artery disease. His regular medications were eso-
meprazole, metroprotol, and levothyroxine. His family
history is notable for coronary artery disease (father),
deep vein thrombosis (DVT) (mother), and brain tumor
(sister).
The initial audiogram at presentation revealed nor-
mal hearing 250–500 Hz and a mild-to-severe, moder-
ately sloping sensorineural loss above 1000 Hz in the
better, left ear. The right ear revealed a severe sensor-
ineural loss with relatively “flat” configuration from 250
to 2000 Hz, with a sharply sloping profound loss above
2000 Hz (Fig. 1). Speech audiometry in the left ear re-
vealed a speech recognition threshold (SRT) of 15 dBHL
and a word recognition score (WRS) of 100%, obtained
using recorded NU-6 materials, full-list, female talker.
In the right ear an SRT could not be measured; how-
ever, a speech awareness threshold (SAT) of 65 dB
HL was obtained and was in good agreement with
the pure tone findings. Word recognition was not eval-
uated in the right ear. Immittance audiometry revealed
normal tympanograms, tympanicmembrane compliance,
middle-ear pressures, and physical volume test (PVT), bi-
laterally. Ipsilateral acoustic reflex thresholds were pres-
ent at normal levels in the left ear and absent in the right
ear. Otologic examination was normal, bilaterally. The
remainder of the patient’s head and neck examination
was unremarkable. The findings from a comprehensive
metabolic panel (CMP) fromthepriormonthand complete
blood count (CBC) and basic metabolic panel (BMP) from
the current month were all normal. An MRI study was
obtained and reported small vessel disease and no retro-
cochlear pathology. The initial impression was of likely
sudden sensorineural loss in the right ear occurring 4-6
wk prior to presentation that was superimposed upon
prior high-frequency sensorineural loss consistent with
his history of noise exposure and presbycusis.
The patientwas placed on a course of oral steroid (pred-
nisone) taper and, in a follow-up appointment 1 wk later,
the patient reported improvement in hearing in the ear.
The limited prognosis in regard to further improvement
in hearing due to the degree of hearing loss and delay in
treatment were discussed, as were the risks of dizziness,
discomfort, and possible tympanic membrane perforation
from the IT injections. A right IT steroid injection was
then undertaken, using 0.3ml of 20mg/ml dexametha-
sone. For the injection, the patient was placed in a
supine position, with the head turned to the left. Using
a binocular microscope, Phenol was used to anesthetize
the posterior aspect of the tympanic membrane, and a
Figure 1. Patient’s pretreatment right and left ear pure tone air
conduction threshold findings at initial visit.
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27-gauge needle was used to make two small perfora-
tions in this posterior area. The dexamethasone was
injected into the middle ear through these perforations,
and the fluid was then visible through the tympanic
membrane, filling the mesotympanum. The patient
was left in the head-turned supine position for 30 min.
He was then elevated to sitting, and then standing.
There was no vertigo or other discomfort.
At 1 mo follow-up, the patient reported gradual im-
provement in hearing, to such a degree that he no longer
noticed a difference in hearing between ears. The patient
continued to have a slight “rushing” tinnitus in the right
ear, buthe reported that the tinnituswasno longer bother-
some. Physical examination found that the right tympanic
membrane was intact, with a heaped border surrounding
the injection site.
Hearing evaluation revealed improvement in pure
tone thresholds of 20 to 45 dB from 500 to 4000 Hz, with
10 and 15 dB improvement at 6000 and 8000 Hz, re-
spectively, as reported in Figure 2.
Speech audiometry revealed anSRTof 40 dBandWRS
of 90% in the right ear at 40 dB SL. The SRT was
obtained using monitored live voice and a male talker.
WRS on the right ear was obtained with a full-list
recorded presentation of the NU-6 word lists, using
the same female talker, using a different word list.
The patient subsequently underwent a second IT dex-
amethasone injection 1 wk later and tolerated the proce-
dure well. At 1 mo follow-up, now 4 mo after suspected
ISSNHL, the patient reported further subjective improve-
ment in hearing and perceived tinnitus. Results of the
hearing evaluation revealed 15 dB additional improve-
ment at 500 and 1000Hz relative to the second evaluation
(Fig. 3), and the SRT in the treated ear was now essen-
tially unchanged, at 40 dB HL. At 40 dB SL, word recog-
nition remained relatively high at 86% using the same
talker and a different word list.
CONCLUSIONS
While this patient has experienced a very signifi-cant improvement in hearing posttreatment, a
hearing deficit remains, with a slight-to-mild sensorineu-
ral loss from 250 to 2000 Hz, and a moderate-to-severe
sensorineural loss above 2000 Hz. The sensorineural loss
at 2000 Hz and above is a likely result of his noise ex-
posure in farming and other large equipment andmachi-
nery, and presbycusis. At present, however, he does not
feel he has a sufficient communicative handicap with his
current lifestyle to warrant consideration of amplifica-
tion or other rehabilitation procedures. Thus, a recom-
mendation for otolaryngology and audiology evaluation
in 6 mo was made.
There were several factors suggesting that this patient
would not have had such a positive outcome, includinghis
age of 79 yr, themoderately severe to severe hearing loss,
and the 4–6wk treatment delay.Despite this, the authors
and the patient felt that the oral steroid, and later the
IT steroid injection, should be pursued. His significant
improvement raises the question that his hearing loss,
perhaps being particularly steroid responsive, may have
an autoimmune etiology. Additionally, there is the possi-
bility that the improvement in hearing may have been
due to a spontaneous recovery, even though the review
of literature suggests this to be unlikely.
Positive responses such as this to systemic and IT ste-
roid injection treatments further complicate generaliza-
tions concerning treatment of ISSNHL that can be drawn
Figure 2. Patient’s right and left ear pure tone air conduction
threshold findings following initial oral systemic steroid treatment
and first IT steroid injection.
Figure 3. Patient’s right and left ear pure tone air conduction
threshold findings following initial oral systemic steroid treatment
and second IT steroid injection.
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from the current body of literature. If an audiologist clini-
cian had made the decision not to refer this patient for
medical treatment and/or an otologist had decided not
to treat this patient, due to the low probability of signif-
icant improvement in hearing, this patient may have
been denied the possibility of improved hearing.
Patients for whom short-term systemic steroids are
not contraindicated may be candidates for such an ap-
proach, and the low-risk IT steroid treatment may be a
possibility for many patients.
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